Ginkgo Bioworks Holdings (DNA) Gross Margin (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Gross Margin for 7 consecutive years, with 91.47% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin rose 522.0% year-over-year to 91.47%; the trailing twelve-month figure through Jun 2026 stood at 83.07% (down 408.0% YoY), and the FY2025 full-year result was 81.48%, down 155.0% from the prior year.
• Gross Margin grew to 91.47% in Q2 2026 per DNA's latest filing, from 84.09% in the prior quarter.
• Across five years, Gross Margin topped out at 100.36% in Q4 2023 and bottomed at 54.08% in Q1 2022.
• Historically, Gross Margin has averaged 80.05% across 5 years, with a median of 82.49% in 2024.
• The sharpest annual moves came in 2022 and 2024: Gross Margin soared 4532 bps in 2022, then plunged 1758 bps in 2024.
• Over 5 years, Gross Margin stood at 90.26% in 2022, then grew by 11 bps to 100.36% in 2023, then decreased by 18 bps to 82.77% in 2024, then slipped by 1 bps to 82.2% in 2025, then increased by 11 bps to 91.47% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 91.47%, 84.09%, and 82.2% for Q2 2026, Q1 2026, and Q4 2025 respectively.